UC Rated a Good Investment by Top Credit Rating Agencies
The University of Cincinnati received good news yesterday. Despite budget problems throughout the State of Ohio, both Moody's and Standard & Poor's affirmed the University's bond ratings of Aa3 and AA respectively, in conjunction with $20 million of refinancing bonds to be issued this week. The good news, in short, is that our ratings did not drop. Our current ratings have a positive impact on the university's budget.
Positive factors cited by the rating agencies include:
* stable enrollment, with improved yield on a lower number of applications
* a strong security pledge of all unrestricted revenues except the state appropriation
* quasi-endowment funds increased by $60 million through the French bequest
Largely because of the state's predicament, the agencies affirmed our ratings "with a negative outlook," indicating that they are aware of the potential for future drops. For example, if the uncertain state budget situation results in even more cuts passed down to higher education, or as significant amounts of the university's prospective debt actually gets issued creating a higher debt burden without corresponding revenue increases, the stage has been set for the agencies to change our rating. I should note that, even if our ratings drop back to A1 and AA-, those are still good, investment-quality bond ratings.
Moody's upgraded the university from A1 to Aa3 in December 1999, and S&P upgraded the university from AA- to AA in August, 1997. UC had a "stable" outlook, until last spring when both agencies changed the outlook to "negative," primarily citing the state budget environment. We are working hard to continue presenting the best case to the agencies, and I am very glad we came through this rating with current ratings affirmed. Still, we must work diligently over the next year to preserve our ratings in the next review.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.